Mirum Pharmaceuticals, Inc. MIRM Cost of Sales
Cost of Sales at other companies
Other financials
Where this comes from
Reported directly by Mirum Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept mirm:CostOfSales.
The official record: Mirum Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mirum Pharmaceuticals, Inc.'s cost of sales.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mirum Pharmaceuticals, Inc.'s cost of sales?
- Mirum Pharmaceuticals, Inc. (MIRM) reported cost of sales of $28.81M in Q1 2026.
- How has Mirum Pharmaceuticals, Inc.'s cost of sales changed year-over-year?
- Mirum Pharmaceuticals, Inc.'s cost of sales increased by 25.1% year-over-year, from $23.02M to $28.81M.
- What is the long-term trend for Mirum Pharmaceuticals, Inc.'s cost of sales?
- Over 3 years (2022 to 2025), Mirum Pharmaceuticals, Inc.'s cost of sales has grown at a 100.8% compound annual growth rate (CAGR), from $12.37M to $100.24M.
- What does cost of sales mean?
- This metric represents the direct costs attributable to the production and distribution of the company's pharmaceutical products, including raw materials, manufacturing overhead, and logistics. It serves as a key indicator of production efficiency and the direct margin impact of the company's commercialized therapies. Monitoring this figure helps investors assess the scalability of the product portfolio and the effectiveness of supply chain management.